Evidence map›Paper›PMID 34809714›Full record

ArticleClinical epigenetics2021

Correction to: Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS‑CoV‑2 infectivity.

Maria Laura Saiz, Marta L DeDiego, Darío López-García, Viviana Corte-Iglesias, Aroa Baragaño-Raneros, Ivan Astola, Victor Asensi, Carlos López-Larrea, Beatriz Suarez-Alvarez

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Maria Laura Saiz *Translational Immunology Laboratory, Health Research Institute of Asturias (ISPA), Oviedo, Spain.
Marta L DeDiego *Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Darío López-GarcíaDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
Viviana Corte-IglesiasTranslational Immunology Laboratory, Health Research Institute of Asturias (ISPA), Oviedo, Spain.
Aroa Baragaño-RanerosTranslational Immunology Laboratory, Health Research Institute of Asturias (ISPA), Oviedo, Spain.
Ivan AstolaIntensive Care Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Victor AsensiInfectious Diseases Unit, Translational Research in Infectious Diseases Group, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), OviedoOviedo, Spain.
Carlos López-LarreaTranslational Immunology Laboratory, Health Research Institute of Asturias (ISPA), Oviedo, Spain. inmuno@hca.es.
Beatriz Suarez-AlvarezTranslational Immunology Laboratory, Health Research Institute of Asturias (ISPA), Oviedo, Spain.ORCID http://orcid.org/0000-0002-3431-4206

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34809714
PMCPMC8608228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.